MITSUBISHI TANABE , Outperform - Invokana: Nice to Have A Clean Label, Yet A Long Way To Go Before Gaining Full Confidence! - Reports Corner

For complete information about the report, please visit our website

https://www.reportscorner.com/reports/14937/MITSUBISHI-TANABE-,-Outperform---Invokana:-Nice-to-Have-A-Clean-Label,-Yet-A-Long-Way-To-Go-Before-Gaining-Full-Confidence!-/

Invokana clean label thrills many on the street rising hopes that Invokana sales could cross $2.5b+ at peak.  However we think that CV issues (dose dependent increase in LDL, CV events observed in first 30 days in CANVAS study),  associated genital/UTI infections, compromised efficacy in renally impaired patients and  long term safety study requirements by FDA (Table 1), should be seen in conjunction with the 'clean label'. 

Global Pharmaceutical & Biotechnology Outlook 2013 Japan Pharma - Reports Corner

For complete information about the report, please visit our website

https://www.reportscorner.com/reports/10015/Global-Pharmaceutical-&-Biotechnology-Outlook-2013:-Japan-Pharma/

The coming years will see Japan pharma regaining its status as innovator driven with Edoxaban for Daiichi Sankyo, Canagliflozin for Mitsubishi Tanabe, and Dolutegravir for Shionogi bringing the good times back for the respective companies in 2013 and carrying enough potential to change global market dynamics in the anticoagulant, diabetes and HIV space resp. We think that the massive ~$45b poured in acquiring innovation by Japanese companies does not justify its value as we find that the key catalysts from Japan are in-house candidates.